Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on June 7, 2017. The report details a corporate action regarding the Company's capital structure, specifically a reverse stock split of its common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change to the Articles of Incorporation and does not contain financial performance data.
Material Changes
- Reverse Stock Split: The Company filed a Certificate of Amendment to effectuate a 1-for-15 reverse stock split.
- Effective Date: The split became effective on June 9, 2017.
- Share Conversion: Every 15 shares of issued and outstanding common stock were converted into one share of common stock.
- Fractional Shares: No fractional shares were issued; holders entitled to a fraction received a whole share instead.
- Adjustments: All outstanding options, warrants, and convertible securities were proportionately adjusted by dividing the share count by 15 and multiplying the exercise or conversion price by 15.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks beyond the corporate action. The reverse stock split was authorized by shareholders on September 15, 2016, within a range of 1-for-8 to 1-for-20, with the Board selecting the 1-for-15 ratio.
Investor Verification Checklist
- Verify the post-split share count and adjusted exercise prices for any held options or warrants.
- Confirm the effective date of June 9, 2017, for trading purposes.
- Review the Certificate of Amendment (Exhibit 3.1) for complete legal terms.
- Check the press release (Exhibit 99.1) for additional context on the rationale for the split.